Company Overview and News

7
EGN / Energen Corp. / Corvex Management LP - AMENDMENT NO. 13 TO SCHEDULE 13D (Activist Investment)

2018-06-18 sec.gov
Amendment No. 13 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
EGN

11
EGN / Energen Corp. / Corvex Management LP - AMENDMENT NO. 13 TO SCHEDULE 13D (Activist Investment)

2018-06-18 sec.gov
Amendment No. 13 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
EGN

7
Hartstreet: Icahn And Corvex See Value In Energen, And We See Production Improvements

2018-06-18 seekingalpha
Energen (EGN) has been in the news lately with Icahn and Corvex mulling a bid to buy the company. The question seems to be why EGN? There are a number of reasons why the company is attractive. The shares seem undervalued at current valuations. This seems linked to EGN's recent production improvements per location. EGN is a Permian pure play, and has continued to improve production results. The Permian has the most valued acreage, but widening differentials are providing value in some names.
EGN

115
Bulletproof Investing Performance Update: Week 28

2018-06-10 seekingalpha
It's been six months since I presented 4 hedged portfolios and 10 top names in week 28 of my Marketplace service (December 8th). Here's how everything did.
ODFL ALGN MGLN SQ CAT PHM THO GDOT DLTR DHI EGN URI NSP ODLF PPC

8
EGN / Energen Corp. 8-K (Current Report)

2018-06-08 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
EGN

33
Oil boom bottleneck costs Permian investors US$1b a day

2018-06-08 malaymail
NEW YORK, June 8 — More than US$1 billion (RM3.97 billion) a day. That’s how much value a Permian Basin pipeline crunch wiped out from the explorers most focused on the booming US shale region in two weeks.
XOM PE CXO EPD EOG DK RSPP CVX HFC LPI EGN CVRR MMP OXY FANG

26
Oil Boom Bottleneck Costs Permian Investors $1B a Day

2018-06-07 rigzone
(Bloomberg) -- More than $1 billion a day. That’s how much value a Permian Basin pipeline crunch wiped out from the explorers most focused on the booming U.S. shale region in two weeks.
XOM RSPP CVX LPI EGN PE CXO OXY FANG EOG

19
The Play Between Energy, Economy And Technological Change

2018-06-01 seekingalpha
While the Permian Basin is a proxy for U.S. oil production, other economic forces play a role in the direction supply takes.
RSPP XOM CVX EGN PXD CXO OXY

8
Corvex, Icahn to Mull Bid for Oil and Gas Producer Energen

2018-05-21 rigzone
BOSTON, May 21 (Reuters) - Activist hedge fund manager Keith Meister and billionaire investor Carl Icahn said they may try to buy oil and gas producer Energen Corp, according to a regulatory filing made on Monday.
EGN DTK

107
Icahn teams up with protege in Energen deal that makes for an activist trifecta

2018-05-21 cnbc
Carl Icahn is joining his protege, Keith Meister, in a deal that may ultimately lead to their purchase of oil and gas producer Energen Corp.
CKRGZ CHKVP CHKDH CHKVZ HRI IEP CHKDG CHKWZ CHKDJ CHKDP CHK.WI CHK EGN CHK.PRD HTZ

7
Corvex and Icahn to mull making a bid for Energen

2018-05-21 reuters
BOSTON (Reuters) - Activist investor Keith Meister on Monday reunited with billionaire investor Carl Icahn and said in a regulatory filing that they may try to buy oil and gas producer Energen Corp. (EGN.N).
EGN DTK

7
EGN / Energen Corp. / Corvex Management LP - SCHEDULE 13D AMENDMENT NO. 12 (Activist Investment)

2018-05-21 sec.gov
Schedule 13D Amendment No. 12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
EGN

8
EGN / Energen Corp. / Corvex Management LP - SCHEDULE 13D AMENDMENT NO. 12 (Activist Investment)

2018-05-21 sec.gov
Schedule 13D Amendment No. 12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
EGN

1239
Tracking John Paulson's Paulson & Co. Portfolio - Q1 2018 Update

2018-05-18 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking John Paulson's Paulson & Co. Portfolio series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017.
SNI BGX DISCB VST DISCA TSU TWX AU DISCK ENL BGLF STAY SHPG VIAB HAWK AABA DST OSG.WI SSNC AEM INSW AGG SYMX AET DISC FOX TMUSP TMUS RGORF VRX BKD UTX GOLD BX 2840 TWC OGISD NSW OGSRW MDT BGB SGYP SES CZR OGSWW OGISZ XLGLF SCMP QCOM INSW.WI FOXA OGSBW ENDP NMRK NXPI XL CTL RRS GLD AULGF OSG VRX MYL AGN ODP EGN MON SGYPW HZNP OSGB DISH OVSPW CACQ COL GOLD OVSPA VST.WSA OAS T OVSPD VSTE MNK THM

233
U.S. Shale: NAV Analysis Of Anadarko Basin E&Ps

2018-05-10 seekingalpha
These reports value about 50 US shale exploration and production companies (“E&Ps”) based on their net asset values (“NAV”). Each quarter, I expect to publish new reports with updated quarterly information. Also, because I track a substantial amount of information on each company, from time to time I also intend to publish E&P sector wide trends reports.
ARES.PRA QEP PXD CRZO EQT GPOR SNZYP SN XOG PDCE WLL SRCI SM CTLR HKRCP BCEI HK.WS NFX ARES JONE WPX ESTE CLR ECR CPE WPXP GST-A XEC GST-B DVN GST REN PVA PE CXO EPE SCAZP AXAS GST.PRA GST.PRB AREX RSPP JNEEP EGN SWN JAG CDEV MTDR VNOM PVAYQ COG EOG OAS LPI PVAC HK FANG

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to EGN / Energen Corp. on message board site Silicon Investor.

2026 TeoTwawKi ... 2032 Darkest Interregnum SEGNY: Sega Enterprises Ltd.
Egan Systems (egns) ElGrande, EGND
Sega Enterprises Ltd - (OTC:SEGNY ) REGN
CUSIP: 29265N108